Total Payments
$3,731
2024 Payments
$74.10
Companies
16
Transactions
67
Medicare Patients
3,887
Medicare Billing
$856,078
Payment Breakdown by Category
Consulting$2,113 (56.6%)
Food & Beverage$1,619 (43.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,113 | 1 | 56.6% |
| Food and Beverage | $1,619 | 66 | 43.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $2,113 | 1 | $0 (2023) |
| Amgen Inc. | $299.79 | 16 | $0 (2024) |
| Relypsa, Inc. | $227.57 | 10 | $0 (2020) |
| Otsuka America Pharmaceutical, Inc. | $183.45 | 10 | $0 (2020) |
| BARD PERIPHERAL VASCULAR, INC. | $135.33 | 1 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $134.00 | 2 | $0 (2021) |
| Mallinckrodt LLC | $120.02 | 2 | $0 (2018) |
| Vifor Pharma, Inc. | $119.55 | 5 | $0 (2024) |
| Keryx Biopharmaceuticals, Inc. | $109.95 | 5 | $0 (2018) |
| GENZYME CORPORATION | $57.41 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $74.10 | 3 | Vifor Pharma, Inc. ($56.50) |
| 2023 | $2,188 | 4 | GlaxoSmithKline, LLC. ($2,113) |
| 2022 | $110.57 | 4 | Amgen Inc. ($64.56) |
| 2021 | $180.19 | 5 | Alexion Pharmaceuticals, Inc. ($117.90) |
| 2020 | $169.85 | 8 | Relypsa, Inc. ($47.82) |
| 2019 | $397.62 | 15 | BARD PERIPHERAL VASCULAR, INC. ($135.33) |
| 2018 | $291.88 | 15 | Amgen Inc. ($76.53) |
| 2017 | $318.99 | 13 | Mallinckrodt LLC ($95.03) |
All Payment Transactions
67 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/17/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: Hyperkalemia | ||||||
| 03/14/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $31.82 | General |
| Category: Hyperkalemia | ||||||
| 01/23/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Nephrology | ||||||
| 11/10/2023 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: Cardiology | ||||||
| 05/23/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $27.01 | General |
| Category: Hyperkalemia | ||||||
| 05/02/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Consulting Fee | Cash or cash equivalent | $2,112.50 | General |
| Category: IMMUNOLOGY | ||||||
| 04/04/2023 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: Hyperkalemia | ||||||
| 12/09/2022 | Amgen Inc. | Parsabiv (Drug), Sensipar | Food and Beverage | In-kind items and services | $25.59 | General |
| Category: Nephrology | ||||||
| 08/19/2022 | Amgen Inc. | Parsabiv (Drug), Sensipar | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: Nephrology | ||||||
| 07/22/2022 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: Nephrology | ||||||
| 03/25/2022 | NxStage Medical, Inc. | — | Food and Beverage | In-kind items and services | $46.01 | General |
| 10/21/2021 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $117.90 | General |
| 10/01/2021 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $12.66 | General |
| Category: Nephrology | ||||||
| 08/18/2021 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $11.33 | General |
| Category: Hyperkalemia | ||||||
| 06/11/2021 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: Nephrology | ||||||
| 05/07/2021 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: Nephrology | ||||||
| 11/10/2020 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: Hyperkalemia | ||||||
| 08/21/2020 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $25.67 | General |
| Category: Nephrology | ||||||
| 07/09/2020 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: NEPHROLOGY | ||||||
| 05/08/2020 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: Hyperkalemia | ||||||
| 03/12/2020 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: Genetic Disease | ||||||
| 02/22/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/07/2020 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: Nephrology | ||||||
| 01/14/2020 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: KRYSTEXXA | ||||||
| 12/30/2019 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: KRYSTEXXA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 821 | 1,840 | $443,238 | $171,498 |
| 2022 | 13 | 944 | 2,379 | $526,497 | $209,083 |
| 2021 | 15 | 994 | 2,708 | $556,251 | $243,134 |
| 2020 | 14 | 1,128 | 2,504 | $583,976 | $232,363 |
Total Patients
3,887
Total Services
9,431
Medicare Billing
$856,078
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 151 | 373 | $79,449 | $36,318 | 45.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 188 | 410 | $61,090 | $26,614 | 43.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 155 | 168 | $70,392 | $23,842 | 33.9% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 21 | 76 | $49,248 | $20,961 | 42.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 146 | 266 | $71,819 | $20,072 | 27.9% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 19 | 81 | $43,740 | $19,261 | 44.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 55 | 354 | $45,182 | $16,261 | 36.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 38 | 62 | $9,734 | $3,628 | 37.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $4,862 | $1,825 | 37.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $3,437 | $1,518 | 44.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 22 | $4,285 | $1,197 | 27.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 219 | 617 | $91,933 | $35,897 | 39.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 92 | 590 | $70,275 | $30,621 | 43.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 150 | 293 | $85,556 | $28,352 | 33.1% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 27 | 95 | $61,560 | $27,072 | 44.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 136 | 309 | $65,817 | $26,016 | 39.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 136 | 147 | $61,593 | $24,023 | 39.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 20 | 81 | $43,740 | $19,836 | 45.4% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 56 | 122 | $19,154 | $7,337 | 38.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 36 | 40 | $11,440 | $4,319 | 37.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 17 | 17 | $3,740 | $2,272 | 60.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 31 | 39 | $8,073 | $2,085 | 25.8% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 13 | 18 | $1,350 | $721.04 | 53.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 11 | $2,266 | $531.87 | 23.5% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 32 | 139 | $90,072 | $41,573 | 46.2% |
About Dr. Nayan Gowda, MD
Dr. Nayan Gowda, MD is a Nephrology healthcare provider based in Lombard, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1922294388.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nayan Gowda, MD has received a total of $3,731 in payments from pharmaceutical and medical device companies, with $74.10 received in 2024. These payments were reported across 67 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($2,113).
As a Medicare-enrolled provider, Gowda has provided services to 3,887 Medicare beneficiaries, totaling 9,431 services with total Medicare billing of $856,078. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Lombard, IL
- Active Since 09/19/2007
- Last Updated 01/25/2023
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1922294388
Products in Payments
- BENLYSTA (Biological) $2,113
- Veltassa (Drug) $347.12
- Parsabiv (Drug) $155.95
- JYNARQUE (Drug) $137.31
- Parsabiv (Biological) $126.24
- ACTHAR (Biological) $120.02
- Auryxia (Drug) $109.95
- Rayaldee (Drug) $47.54
- SAMSCA (Drug) $46.14
- Rituxan (Biological) $41.06
- LOKELMA (Drug) $37.85
- KRYSTEXXA (Biological) $35.39
- FUROSCIX (Drug) $24.02
- FABRAZYME (Biological) $21.53
- FABRAZYME (Drug) $18.79
- Aranesp (Biological) $17.60
- FABRY-DISEASE (Drug) $17.09
- SOLIRIS (Drug) $16.10
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.